Envista (NYSE:NVST) Price Target Cut to $17.50 by Analysts at The Goldman Sachs Group

Envista (NYSE:NVST) had its target price decreased by The Goldman Sachs Group from $20.00 to $17.50 in a research note released on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

NVST has been the subject of a number of other reports. Morgan Stanley cut Envista from an overweight rating to an equal weight rating and cut their price objective for the stock from $33.00 to $21.00 in a report on Friday, April 26th. Robert W. Baird decreased their price target on shares of Envista from $22.00 to $19.00 and set a neutral rating on the stock in a research note on Thursday. TheStreet cut shares of Envista from a c rating to a d+ rating in a research note on Wednesday, February 7th. Leerink Partnrs reiterated an underperform rating on shares of Envista in a research report on Monday, February 26th. Finally, Jefferies Financial Group lowered shares of Envista from a buy rating to a hold rating and cut their price target for the company from $30.00 to $23.00 in a research report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Envista currently has an average rating of Hold and a consensus price target of $25.86.

Envista Price Performance

Shares of NVST stock traded down $0.81 during trading on Friday, hitting $19.00. The company had a trading volume of 2,239,656 shares, compared to its average volume of 1,979,218. The stock’s 50-day moving average is $20.66 and its two-hundred day moving average is $22.53. The stock has a market capitalization of $3.27 billion, a price-to-earnings ratio of -26.40, a price-to-earnings-growth ratio of 3.83 and a beta of 1.35. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 0.34. Envista has a 52 week low of $18.09 and a 52 week high of $36.74.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). Envista had a positive return on equity of 5.84% and a negative net margin of 4.70%. The company had revenue of $623.60 million during the quarter, compared to the consensus estimate of $634.85 million. During the same period in the previous year, the company earned $0.38 EPS. Envista’s quarterly revenue was down .6% on a year-over-year basis. As a group, analysts predict that Envista will post 1.38 EPS for the current fiscal year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Retirement Systems of Alabama lifted its position in shares of Envista by 2.0% in the 4th quarter. Retirement Systems of Alabama now owns 504,572 shares of the company’s stock worth $12,140,000 after purchasing an additional 10,120 shares during the period. Foundry Partners LLC bought a new stake in Envista during the 4th quarter valued at approximately $3,571,000. Raymond James & Associates grew its holdings in shares of Envista by 820.6% during the 4th quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock worth $9,822,000 after acquiring an additional 363,875 shares during the period. River Road Asset Management LLC bought a new position in shares of Envista in the 4th quarter worth approximately $54,931,000. Finally, DAVENPORT & Co LLC purchased a new position in shares of Envista in the 4th quarter valued at approximately $13,233,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.